A therapy that decreases the bulk of the retinoblastoma tumor using Wnt activator proteins would need to be used in combination with inhibitors of the Wnt pathway that are specifically targeted to the stem cell population, potentially by using ABCG2 or other cancer stem cell marker genes. This evidence concerns the gene ABCG2 and neoplasm.